Novavax/King Estrasorb approval
Executive Summary
Novavax and King will launch topical estrogen emulsion Estrasorb in early 2004 via 125 sales reps, following FDA approval Oct. 9. Hormone therapy approved for vasomotor symptoms; carries class warning from Women's Health Initiative study. Former Lilly exec Ford Lynch tapped to head sales and marketing efforts. NDA was submitted in June 2001 but was withdrawn and resubmitted Sept. 9, 2002. FDA later extended the review time by three months (1"The Pink Sheet" June 30, 2003, In Brief)...
You may also be interested in...
Novavax Estrasorb review extension
FDA extends Novavax Estrasorb July 12 user fee date by three months to Oct. 10. Company expects extension of review period will not delay its planned launch for the first quarter of 2004. Novavax voluntarily withdrew the estrogen replacement cream NDA in April 2002 due to chemistry, manufacturing and controls concerns (1"The Pink Sheet" April 29, 2002, In Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.